Disease | Mechanism of action | Result | References |
---|---|---|---|
Pro-tumor | |||
 AML | Suppresses C/EBPα expression | Enhances AML progression | [50] |
Enhances the expression of anti-apoptotic BCL2 | Enhances AML progression | [51] | |
 CML | Stimulates the ERK pathway | Increases cell proliferation and drug resistance | [12] |
 T-ALL | Decreases C/EBPα expression | Promotes the growth and maintenance of T-ALL cells | [55] |
 Liver cancer | Increases YAP stabilization | Promotes cancer cell proliferation | [56] |
Interacts with PCBP2 and triggers the UPS | Reduces Ub flux and decrease the oxidative damage | [58] | |
 Lung cancer | Decreases expression levels of C/EBPα | Accelerates cell proliferation and tumor growth | [59] |
 Malignant melanomas | Suppresses FOXO | Promotes cell proliferation, colony formation, maintenance, and progression | [63] |
 Human melanoma tissues and cell line |  | Migration and invasion | [64] |
 OS cell line |  | Enhances the malignant capacity | [10] |
 CRC | Suppresses p21 expression | Improves cell growth and progression, and block cellular senescence | [14] |
 GBM | Interacts with MAP3K1 | Enhances resistance to chemotherapy and radiotherapy | [8] |
 Pancreatic cancer tissue | Suppresses the p53/MDM2 complex | Promotes resistance to anti-cancer therapy | [66] |
 LSCC | Interacts with XIST | Enhances proliferation and migration | [69] |
 OSCC | Interacts with TRIM | Facilitates the development of OSCC | [71] |
Anti-tumor | |||
 Myeloid leukemia | Suppresses the Wnt pathway, stimulates activation of p38 stress signaling | Reduces cell propagation | [53] |